tbuckley/cabot-search huggingface dataset:
Depression in Sarcoidosis
Authors: BETTY CHANG, JOANNE STEIMEL, DAVID R. MOLLER, ROBERT P. BAUGHMAN, MARC A. JUDSON, HENRY YEAGER, ALVIN S. TEIRSTEIN, MILTON D. ROSSMAN, CYNTHIA S. RAND
Journal: American Journal of Respiratory and Critical Care Medicine (2001)

Sarcoidosis, a chronic, multisystem disease, impacts quality of life and may increase depression risk. No previous study has reported the depression prevalence among U.S. sarcoid patients. This cross-sectional study examined sociodemographic and disease morbidity factors associated with depression. Patients diagnosed for > or = 1 yr and treated at one of six centers were eligible (n = 176); 154 completed a questionnaire of demographics, treatment, access to medical care, and a short-form Center for Epidemiologic Studies- Depression Scale (CES-D). The primary outcome variable was a CES-D score of > or = 9, indicating clinical depression. The prevalence of depression was 60%. Gender, income, access to medical care, dyspnea on exertion, and number of systems involved were associated with depression. Female sex, decreased access to medical care, and increased dyspnea predicted depression (odds ratio [OR] = 3.33, 11.64, and 2.78, respectively) after adjusting for race, income, and steroid therapy. Despite tertiary care access, patients reported medical care limitation. Health care providers must be sensitive to multiple barriers faced by chronic sarcoid patients; acknowledging depression risk and improving access to medical care will promote better overall health among sarcoid patients. Future studies of sarcoidosis will need to address depression diagnosis and treatment.
UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V
Authors: H.T. Jacobe, R. Cayce, J. Nguyen
Journal: British Journal of Dermatology (2008)

Background Studies suggest ultraviolet (UV) A1 phototherapy is efficacious and safe in treating a variety of skin disorders. However, most reports evaluating the benefits of UVA1 phototherapy have been from Europe, focusing on a predominantly Caucasian population. Darker skin types have been evaluated only sparingly; none the less, it is widely held that these patients respond poorly to UVA1 phototherapy due to increased pigmentation. Objectives We aim to compare efficacy (clinical improvement scores) of UVA1 phototherapy among Fitzpatrick skin types. Methods A retrospective analysis of 101 patients receiving UVA1 treatment at the University of Texas Southwestern Medical Center in Dallas, TX was performed. Data on Fitzpatrick skin type and cumulative UVA1 doses were collected. Clinical improvement scores based on body surface area, erythema, induration, sclerosis, pigmentation, and symptoms of pain or pruritus were obtained. Results In the population studied, with morphoea and scleroderma being the most frequent diagnoses, improvement scores from UVA1 phototherapy and mean cumulative UVA1 doses were not significantly different among the Fitzpatrick skin types evaluated. Furthermore, little or no correlation was found between improvement score and skin type. Conclusions Data indicate skin pigmentation as graded by Fitzpatrick skin type does not significantly influence the efficacy of UVA1 phototherapy. Thus, UVA1 should be considered as a therapeutic option in more darkly pigmented patients.
Acceleration of F‐cell production in response to experimentally induced anemia in adult baboons (Papio cynocephalus)
Authors: Peter E. Nute, Th. Papayannopoulou, P. Chen, G. Stamatoyannopoulos
Journal: American Journal of Hematology (1980)

Abstract Changes in levels of fetal hemoglobin and Hb F‐containing erythrocytes (F‐cells) were monitored in adult baboons (Papio cynocephalus) rendered acutely anemic by phenylhydrazine or phlebotomy, or chronically anemic by a combination of both forms of treatment. The highest levels of Hb F were observed in acutely anemic animals from 21 to 29 days after initiation of treatment and represented 2.2‐ to 5.6‐fold increases over levels measured prior to induction of anemia. Changes in F‐cell levels correlated well with changes in proportions of Hb F (r = 0.89), and peak F‐cell levels exceeded initial levels by factors ranging from 6 to 11.7. These data confirm previous findings and indicate that adult baboons respond to severe anemic stress by producing increased numbers of Hb F‐containing cells. Thus, P cynocephalus appears to be a suitable model for the study, in vivo, of Hb F regulation in man, since it is likely that changes in Hb F production are mediated by similar mechanisms in both species.
1113-159 Left ventricular modification by myocor myosplint in patients with dilated cardiomyopathy: A three-month follow-up study with real-time 3-D and 2-D echo
Authors: Jian Xin Qin, Takahiro Shiota, Joon Han Shin, Giuseppe Saracino, Kiyotaka Fukam, Michael K Banbury, James B Young, Patrick M McCarthy, James D Thomas
Journal: Journal of the American College of Cardiology (2004)
Erratum: GOAT links dietary lipids with the endocrine control of energy balance
Authors: Henriette Kirchner, Jesus A Gutierrez, Patricia J Solenberg, Paul T Pfluger, Traci A Czyzyk, Jill A Willency, Annette Schürmann, Hans-Georg Joost, Ronald J Jandacek, John E Hale, Mark L Heiman, Matthias H Tschöp
Journal: Nature Medicine (2009)
Bad medicine: general practice
Authors: Des Spence
Journal: BMJ (2010)

In 2004 a 1000 point plan called the quality and outcomes framework (QOF) was introduced with a fanfare into general practice in England, Wales, and Scotland. This initiative was to replace perceived poor quality and poorly coordinated care with evidenced based medicine—taking research from theory into practice. It was expensive, at a cost of £1bn, but health improvement would be rapid and real and worth it. Has it worked?

We slap ourselves on the back because we have seen recorded reductions in glycated haemoglobin HbA1C, blood pressure, and cholesterol. But an experiment this large …
Holocaust Survivors' Mental Health
Authors: Burton C. Einspruch
Journal: JAMA (1995)

It would be a mistake to think that, simply because the oven fires have long been extinguished and their grisly remains have been interred, the aftermath of the Holocaust is still not an active element in the lives of many people. The box office success of<i>Schindler's List</i>, a penetrating and welcome portrayal of the plight of a small group of Jews destined to be survivors, not only reawakened popular interest in the Holocaust but also reopened scars in many who, unfortunately, need no movie to revive horrific recollections of their experiences. T. L. Brink, PhD, a faculty member of Grafton Hills College and Loma Linda University, is a distinguished and experienced scientist and productive contributor to the gerontological literature. His purpose in writing this book is to "pull together chapters written by mental health professionals working with this population [aging Holocaust survivors] in Israel and the United States." A
EPIDEMIOLOGY OF RURAL TYPHOID
Authors: D. G. GILL
Journal: JAMA (1927)

Typhoid has been steadily decreasing throughout the United States, but unfortunately is still a major problem in the Southern states. The death rates and total deaths from this disease in Alabama during the last decade are shown in chart 1. An analysis<sup>1</sup>of the location of cases and deaths during 1924 and 1925 has shown that it is the small town and strictly rural districts that supply most of the cases. The highest rates occur in the towns with populations under 1,000, while 80 per cent of the typhoid occurs in the rural areas and towns with populations up to 5,000. Conditions favoring the occurrence and spread of the disease in this section of the population are of interest. Water supplies, milk supplies and sanitation are naturally the first considerations. Water supplies as a rule are not community supplies except in the larger places. Wells of varying depth are the
Recombinant Hirudin in Clinical Practice
Authors: Andreas Greinacher, Norbert Lubenow
Journal: Circulation (2001)

Abstract —Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin—lepirudin—has been approved is treatment of heparin-induced thrombocytopenia (HIT). Also, the recently completed trials for use of lepirudin in unstable angina indicate a potentially new indication. This review describes pharmacology and clinical applications of lepirudin with an emphasis on HIT and unstable angina. An overview of usage of lepirudin in acute coronary syndromes is given, as well as a summary of rare indications for lepirudin, such as extracorporeal circulation, for which comprehensive data are lacking.
Oral steroid in the treatment of carpal tunnel syndrome
Authors: A C F HUI
Journal: Annals of the Rheumatic Diseases (2001)

A range of options are available for the conservative treatment of carpal tunnel syndrome (CTS).1-4 Non-operative methods include immobilisation of the affected hand with wrist splint; local injection of steroids and drugs such as diuretics and non-steroidal anti-inflammatory drugs.6-11 These oral drugs are thought to decrease the volume of swollen tissue within the CTS and are widely used, but there is limited clinical evidence for their role.

This prospective randomised, double blind, placebo controlled study aimed at evaluating the effect of oral steroids in the symptomatic treatment of CTS. We recruited patients with newly diagnosed CTS of more than three months' duration with confirmatory electrophysiological results (prolonged median nerve distal motor latencies >4 ms or median ulnar palmar sensory latency difference >0.5 ms) including electromyographic recordings of the abductor …
SPONTANEOUS VENTRICULOGRAPHY FROM RUPTURED BRAIN ABSCESS
Authors: Louis A. Levison
Journal: JAMA (1927)

This case is worthy of record and comment for two reasons: First, spontaneous rupture of a brain abscess into the lateral ventricle and the roentgen-ray record of it are extremely rare, and second, the clinical picture of an acute ventriculitis or an acute ependymitis is rarely seen and its symptomatology has been rarely noted. <h3>REPORT OF CASE</h3> L. N., a student, aged 11, was taken sick about the middle of January, 1926, with a rhinitis and coryza which did not give him much trouble for a period of one week. Signs of a right-sided purulent frontal sinusitis then appeared, for which he was treated by aspiration with the usual nasal suction apparatus. Four or five such treatments were given, and the discharge of pus from the nose became definitely lessened. He was not confined to his bed or to his home during this period of his illness. The tissues
Recent Developments in the Treatment of Multiple Myeloma.
Authors: Jack Brook
Journal: Annals of Internal Medicine (1964)

s1 October 1964Recent Developments in the Treatment of Multiple Myeloma.Jack Brook, M.D., F.A.C.P., Joseph R. Bateman, M.D. (Associate), Jesse L. Steinfeld, M.D., F.A.C.P.Jack Brook, M.D., F.A.C.P.Search for more papers by this author, Joseph R. Bateman, M.D. (Associate)Search for more papers by this author, Jesse L. Steinfeld, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-4-813_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptUntil the recent introduction of phenylalanine mustard, the chemotherapy of multiple myeloma has been unsatisfactory. The use of agents such as urethane, stilbamidine derivatives, corticosteroids, radioactive phosphorus, mitomycin C, or combination of agents has not resulted in uniformly observed, objective responses in large numbers of patients. Although X-ray therapy and corticosteroids have been of some benefit, each of these agents alone has not been effective in producing either marked objective responses or increased survival.Phenylalanine mustard, an oral alkylating agent, had been shown to have an anti-tumor effect, with the L-isomer (Melphalan, L-Sarcolysin) being most effective against animal and human... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Jack Brook, M.D., F.A.C.P.; Joseph R. Bateman, M.D. (Associate); Jesse L. Steinfeld, M.D., F.A.C.P.Affiliations: Long Beach, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1964Volume 61, Issue 4Page: 813-814KeywordsChemotherapyCorticosteroid therapyMultiple myelomaPhenylalaninePhosphorus ePublished: 1 December 2008 Issue Published: 1 October 1964 PDF downloadLoading ...
Learning from the Dying
Authors: Susan D. Block, J. Andrew Billings
Journal: New England Journal of Medicine (2005)

Interview with Dr. Susan Block and medical student Christie Sullivan on Sullivan's first experience with a terminally ill patient. (08:24)Download "I thought I would find out what death actually is. I thought I would learn the proper words to speak. . . . I thought I would leave with answers to my questions about the end of life and how people cope with dying. . . . I hoped there would be a protocol to follow when a patient dies that would protect me from the suffering and grief. My experiences throughout this course have proven to me that to have answers to these questions would make me nonhuman."— Mauro Zappaterra, Harvard Medical School, Class of 2007Teaching about . . .
Lesson of the week: Narcolepsy mistaken for epilepsy
Authors: A. Zeman
Journal: BMJ (2001)

Narcolepsy is common: its cardinal symptoms can give rise to confusion with epilepsy 

Narcolepsy is a distinctive but underdiagnosed disorder of sleep and waking. Its cardinal manifestations are: ( a ) excessive daytime sleepiness, with a tendency to nap repeatedly through the day; ( b ) cataplexy, a loss of muscle tone triggered by emotion, causing immobility for seconds to minutes; ( c ) hypnagogic hallucinations, vivid visual or auditory phenomena, experienced at the onset of sleep; and ( d ) sleep paralysis, an inability to move on first awakening.1

When a patient describes all these symptoms the diagnosis should be straightforward. Diagnostic difficulty arises when patients present with isolated symptoms, or if their story suggests some more familiar diagnosis. We report on three patients recently encountered in whom narcolepsy was initially mistaken for epilepsy. Indeed, Gelineau, the French physician who coined the term “narcolepsy” in 1880, was at pains to distinguish his novel disorder of sleep (narco from the Greek for “sleep” and “lepsy” for taken hold by) from epilepsy, with which he thought it might be confused. 2 3

Case 1— A 26 year old woman was found in the bath “unable to move, speak, or get out.” Her husband reported flickering of the eyelids and muscle twitching. Her speech was slurred as she recovered, over minutes. The referral letter noted a history of short periods of apparent daytime sleep, sometimes at inappropriate moments—for example, during meals—and a tendency to “go weak and limp … if she is having a carry-on or laughing heartily.” The diagnosis at referral was of complex partial seizures; sodium valproate had been prescribed. It emerged that she had clear recall of her period of immobility in the bath: it resembled her episodes of weakness on laughing. On direct questioning she described sleep paralysis and hypnagogic hallucinations. She tended to sleep …
Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-α Expression in Breast Cancer Cells
Authors: Ramzi Seifeddine, Anne Dreiem, Etienne Blanc, Marie-Claude Fulchignoni-Lataud, Marie-Aude Le Frère Belda, Fabrice Lecuru, Thérèse Hervèe Mayi, Nathalie Mazure, Vincent Favaudon, Charbel Massaad, Robert Barouki, Liliane Massaad-Massade
Journal: Cancer Research (2008)

Abstract The transcription factor CCAAT/enhancer binding protein-α (C/EBPα) is involved in the control of cell differentiation and proliferation, and has been suggested to act as a tumor suppressor in several cancers. By using microarray analysis, we have previously shown that hypoxia and estrogen down-regulate C/EBPα mRNA in T-47D breast cancer cells. Here, we have examined the mechanism by which the down-regulation by hypoxia takes place. Using the specific RNA polymerase II inhibitor 5,6-dichlorobenzimidazole-1-β-d-ribofuranoside, the mRNA stability was analyzed under normoxia or hypoxia by quantitative reverse transcription-PCR. Hypoxia reduced the half-life of C/EBPα mRNA by ∼30%. C/EBPα gene promoter studies indicated that hypoxia also repressed the transcription of the gene and identified a hypoxia-responsive element (−522; −527 bp), which binds to hypoxia-inducible factor (HIF)-1α, as essential for down-regulation of C/EBPα transcription in hypoxia. Immunocytochemical analysis showed that C/EBPα was localized in the nucleus at 21% O2, but was mostly cytoplasmic under 1% O2. Knockdown of HIF-1α by RNAi restored C/EBPα to normal levels under hypoxic conditions. Immunohistochemical studies of 10 tumor samples did not show any colocalization of C/EBPα and glucose transporter 1 (used as a marker for hypoxia). Taken together, these results show that hypoxia down-regulates C/EBPα expression in breast cancer cells by several mechanisms, including transcriptional and posttranscriptional effects. The down-regulation of C/EBPα in hypoxia is mediated by HIF-1. [Cancer Res 2008;68(7):2158–65]
Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Authors: C Salvarani, L Boiardi, P Macchioni, F Rossi, P Tartoni, M Casadei Maldini, R Mancini, E Beltrandi, I Portioli
Journal: Annals of the Rheumatic Diseases (1995)

To determine if the presence of low percentages of CD8 positive cells or high levels of soluble interleukin-2 receptors (sIL-2R) define a subgroup of patients with more severe polymyalgia rheumatica and giant cell arteritis (PMR/GCA). 38 PMR/GCA patients were followed up prospectively. Serum levels of sIL-2R and peripheral blood CD8 lymphocytes were measured before the start of corticosteroid treatment, after six months of treatment and at the last visit. Phenotypical analysis of lymphocyte subpopulations was performed with a two colour technique, and assay of sIL-2R was performed using an enzyme-linked immunosorbent kit. Forty four healthy people matched for age and gender comprised a healthy control group. The median duration of follow up was 28 months (range 7-65). Corticosteroid treatment lasted a median of 23.5 months (7-65). Eleven patients (29%) were in remission at the end of follow up; 45% of the patients had at least one relapse or recurrence. Compared with controls, patients with active disease had a significantly lower percentage of CD8 cells and significantly increased sIL-2R levels. Erythrocyte sedimentation rate, C reactive protein, and sIL-2R values were significantly less after six months of steroid treatment compared with before treatment. The percentage of CD8 cells remained significantly lower at six months and the end of follow up compared with controls, while sIL-2R levels remained significantly greater. Patients in whom the percentage of CD8 cells at six months was lower than one SD of the mean of normal controls (26%) had a significantly longer duration of corticosteroid treatment, a greater cumulative dose of prednisone and more relapses or recurrences compared with patients in whom the percentage was in the normal range. The duration of treatment and the cumulative dose of prednisone were not influenced by the percentage of CD8 cells before treatment therapy or by the levels of sIL-2R after six months of treatment. A reduced percentage of CD8 cells after six months of treatment may be a useful outcome parameter which would identify a group of PMR/GCA patients likely to experience more severe disease, defined as longer duration of corticosteroid treatment, higher cumulative dose of prednisone, and relapse or recurrence of disease.
Poetry of Li Bao Nguyen
Authors: Susan Lyon
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
One Registry of Patients with Chronic Renal Failure
Authors: BELDING H. SCRIBNER
Journal: Annals of Internal Medicine (1972)

Letters, Comments, and Corrections1 August 1972One Registry of Patients with Chronic Renal FailureBELDING H. SCRIBNER, M.D.BELDING H. SCRIBNER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-77-2-318_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The other day I wanted to find the answer to a relatively simple but important question: How many new patients in the United States entered the chronic dialysis-transplant population in 1971? The registry of dialysis patients could tell me how many patients started dialysis in 1971 but not how many of those were former transplant patients; and, of course, the registry of transplant patients had no way of showing how many of the transplants were done on former dialysis patients. So it is not possible to answer one of the simplest and most vital questions about chronic...Reference1. SCRIBNER B: Emerging interrelationship between kidney transplantation and regular dialysis. Transplantation Proc 3:1395-1403, 1971 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: BELDING H. SCRIBNER, M.D.Affiliations: University of Washington Department of Medicine Seattle, Wash. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1972Volume 77, Issue 2Page: 318-318KeywordsMedical dialysisRenal failure ePublished: 1 December 2008 Issue Published: 1 August 1972 PDF downloadLoading ...
Raymond George Birch
Authors: Timothy P Finnegan
Journal: BMJ (2004)

Former general practitioner Sittingbourne, Kent (b Gillingham 1915; q St Bartholomew's Hospital, London, 1940), died from biliary peritonitis on 26 May 2004.​2004.




Figure 1




Raymond Birch's qualification in 1940 was delayed by tuberculosis and he spent the second world war as a general practitioner near Sittingbourne and as medical officer to the Home Guard. He was a founder member of the Royal College of General Practitioners, an honorary surgeon to the British Fire Services Association, a medical officer to the British Red Cross Society, and a liveryman of the Worshipful Society of Apothecaries. In retirement he became a guide at Leeds Castle. Predeceased by his wife, Diana, he leaves two daughters and three grandchildren.